Pharmanovia today announced the appointment of Stephan Eder as Chief Executive Officer (CEO) of Pharmanovia, effective today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001710846/en/

Stephan Eder, CEO

Stephan is a highly experienced leader, with over two decades leading teams and businesses in senior roles in multi-national pharma. Most recently, he served on the Executive Committee at Stada, a private equity backed company focusing on Generics, Specialty and Consumer Healthcare, in several commercial roles, most importantly as Head of Europe, leading a business with sales of EUR 3.5bn and over 6,000 employees. Prior to that, Stephan worked at Novartis and latterly moved over to Sandoz and Hexal, where he held a number of senior positions including CEO, Hexal/Sandoz Germany.

Guido Oelkers, Chair of Pharmanovia, commented: “Stephan has a strong track record delivering sustainable growth across diverse businesses. He has demonstrated a high degree of ambition and urgency and is passionate about building strong teams.

“The board welcomes Stephan as the incoming CEO and looks forward to the company’s future development under his leadership.”

Stephan Eder added, “I am excited to join an organisation that not only owns trusted established brands but is poised to launch some exciting innovative medicines in the next couple of years. I am impressed by the team and see a very strong commitment to making a difference to patient’s lives. This sense of purpose coupled with the ongoing support from our shareholders, gives me conviction to lead the company to the next phase of growth.”

Notes to editors

About Pharmanovia

Pharmanovia is a global healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences as well as identifying new chemical entities that complement our existing portfolio to address unmet need.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.

For more information about Pharmanovia, please visit www.pharmanovia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251001710846/en/

For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
07912887250/ communications@pharmanovia.com

Logo

Images

Tags

More Like This

Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President

Kymanox® Announces Evan Edwards as President

The Estée Lauder Companies Announces the Appointment of Stéphane de La Faverie as President and Chief Executive Officer

/C O R R E C T I O N -- Suanfarma/

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth

Generational Change at JAB: Joachim Creus Appointed CEO

Essential Pharma strengthens management team with appointment of Duncan Ferguson as Vice President, Commercial